Credit Suisse Group reissued their in-line rating on shares of TESARO (NASDAQ:TSRO) in a research report report published on Wednesday. They currently have a $141.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $150.00.
A number of other brokerages also recently commented on TSRO. Zacks Investment Research raised TESARO from a sell rating to a hold rating in a research report on Wednesday, November 8th. Cann reissued a buy rating and set a $199.00 price objective on shares of TESARO in a research report on Tuesday, November 7th. Jefferies Group reissued a hold rating and set a $124.00 price objective on shares of TESARO in a research report on Friday, November 3rd. Morgan Stanley reissued an overweight rating and set a $165.00 price objective (down from $181.00) on shares of TESARO in a research report on Wednesday, November 8th. Finally, HC Wainwright reissued a buy rating on shares of TESARO in a research report on Wednesday, November 8th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $133.39.
TESARO (TSRO) traded down $6.32 during midday trading on Wednesday, reaching $55.23. The company’s stock had a trading volume of 4,730,600 shares, compared to its average volume of 1,220,211. TESARO has a 52 week low of $52.20 and a 52 week high of $184.00. The firm has a market cap of $3,000.00, a P/E ratio of -6.02 and a beta of 1.25. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the transaction, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at $690,529.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 40.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of TSRO. Exane Derivatives lifted its stake in TESARO by 137.1% in the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 1,123 shares during the last quarter. Toronto Dominion Bank lifted its stake in TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares during the last quarter. Bourgeon Capital Management LLC purchased a new stake in TESARO in the fourth quarter valued at approximately $211,000. Fox Run Management L.L.C. purchased a new stake in TESARO in the fourth quarter valued at approximately $218,000. Finally, Commonwealth Equity Services Inc purchased a new stake in TESARO in the third quarter valued at approximately $222,000.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3231408/credit-suisse-group-reiterates-in-line-rating-for-tesaro-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.